JustWin Biotechnology Company.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
JustWin Biotechnology Company is dedicated to developing product solutions and strategies that inhibit key proteins. These include antibody drugs for various cancers, different types of fibrosis, rheumatoid arthritis, and atherosclerosis; protein peptides for pet tumors, feline kidney disease, and pet health supplements; diagnostic reagents such as ELISA kits, WB, IP, and IHC antibodies, rapid inflammation tests, and medication and risk assessment; as well as beauty and healthcare products featuring whitening, anti-inflammatory, antioxidant, anti-aging, and anti-allergic properties.
The content above was translated by Ai
Founded Year
2017
Unified Business No.
64954093
Status
Active
Number of Employees
0
Total capital
15,000,000 (NT$)
Location of Company
Taiwan
, Tainan City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The journey of research and innovation, which began with the ideal of controlling "inflammation" and involved overcoming numerous obstacles, recognizes that although inflammation-related diseases cover a very broad spectrum and involve complex and diverse causative proteins, their molecular pathways are still connected by specific common proteins. Therefore, as long as inhibitor development can target the common key proteins in the inflammatory response, abnormal "inflammation" can be effectively controlled.
Under this concept, the JustWin Biotechnology Company. team worked diligently and, after identifying multiple novel pro-inflammatory "key genes" with commonality in inflammatory pathways, immediately embarked on the path of translational medicine applications. There are many ways to control "inflammation"; for example, chemists can develop small molecules to inhibit the activation of inflammatory proteins. However, considering that protein drugs possess advantages such as high specificity, low toxicity, minimal side effects, clear biological functions, and high R&D barriers that make them difficult to replicate, JustWin Biotechnology Company. chose to develop macromolecular proteins and oligopeptide drugs against the aforementioned novel target proteins to drive the development of inhibitors.
"JustWin Biotechnology Company." is a homophone for JustWin, representing the team's ambition for new drug development. Over the years, the JustWin Biotechnology Company. team has continuously developed potential basic academic research achievements. To make the products more applicable and valuable, and coupled with comprehensive patent protection, innovation and entrepreneurship training, and the ability to respond to corresponding market demands, in recent years, by taking over the achievements of the academic research team from National Cheng Kung University, JustWin Biotechnology Company. has combined master's and doctoral graduates from different biotechnology backgrounds. The company aims to create "broad-spectrum drugs" that can treat various inflammation-related diseases such as cancer, fibrosis, degenerative diseases, and autoimmune diseases, and based on this, extends its reach to cosmeceutical/cosmetic applications, diagnostic reagents, and health foods and medicines for the pet market.
Under this concept, the JustWin Biotechnology Company. team worked diligently and, after identifying multiple novel pro-inflammatory "key genes" with commonality in inflammatory pathways, immediately embarked on the path of translational medicine applications. There are many ways to control "inflammation"; for example, chemists can develop small molecules to inhibit the activation of inflammatory proteins. However, considering that protein drugs possess advantages such as high specificity, low toxicity, minimal side effects, clear biological functions, and high R&D barriers that make them difficult to replicate, JustWin Biotechnology Company. chose to develop macromolecular proteins and oligopeptide drugs against the aforementioned novel target proteins to drive the development of inhibitors.
"JustWin Biotechnology Company." is a homophone for JustWin, representing the team's ambition for new drug development. Over the years, the JustWin Biotechnology Company. team has continuously developed potential basic academic research achievements. To make the products more applicable and valuable, and coupled with comprehensive patent protection, innovation and entrepreneurship training, and the ability to respond to corresponding market demands, in recent years, by taking over the achievements of the academic research team from National Cheng Kung University, JustWin Biotechnology Company. has combined master's and doctoral graduates from different biotechnology backgrounds. The company aims to create "broad-spectrum drugs" that can treat various inflammation-related diseases such as cancer, fibrosis, degenerative diseases, and autoimmune diseases, and based on this, extends its reach to cosmeceutical/cosmetic applications, diagnostic reagents, and health foods and medicines for the pet market.
The content above was translated by Ai
